Search

Displaying results 4161 - 4170 of 10000 in total
  1. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.

  2. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    The excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study. … Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system.

  3. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

  4. Drug

    Indigo

    go.drugbank.com/drugs/DB16862
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate

    go.drugbank.com/drugs/DB02643
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate
  6. Drug

    Cyromazine

    go.drugbank.com/drugs/DB20549
    Experimental

    Cyromazine is a small molecule drug. Cyromazine has a monoisotopic molecular weight of 166.1 Da.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions

  10. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.